These findings shed light on a novel regulatory mechanism involving FGF12 and β‐Trcp that modulates the MDM2 protein level, and highlights the potential therapeutic relevance of targeting this interaction for diseases associated with MDM2 dysregulation, such as psoriasis. Here, FGF12 is linked to psoriasis.